Angelini Pharma acquires Arvelle Therapeutics Angelini Pharma and Arvelle Therapeutics have agreed on the 4th January 2021 a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million. Arvelle Therapeutics is a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders and epilepsy. This […]
Read MoreOn October 18th, a week devoted to celebrating the work of infection preventionists (IPs) begins worldwide. In these difficult times, IPs have been guiding the frontline healthcare workers — and often suiting up right alongside them — to slow the spread of COVID-19. IPs in healthcare facilities the world over […]
Read More